Tuesday, December 10, 2013 | 8:30 AM - 4:30 PM
Speakers: Frank M. LaFerla (University of California, Irvine), Sylvain E. Lesné (University of Minnesota), Bingwei Lu (Stanford University School of Medicine), Lennart Mucke (Gladstone Institute of Neurological Disease), Ralph A. Nixon (Nathan Kline Institute), Franck Polleux (Columbia University), Terrence Town (University of Southern California), Tony Wyss-Coray (Stanford University School of Medicine)
Organizers: Ken Jones (Forest Research Institute), Robert Martone (Covance Biomarker Center of Excellence),
Robert B. Nelson (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)
This symposium explores how efforts to better integrate our understanding of neuritic plaques and neurofibrillary tangles—the two hallmark pathologies of Alzheimer's disease—are leading to a 'truce' between former rivals in the quest for therapies.
Wednesday, December 11, 2013 | 7:00 PM - 8:30 PM
Featuring: Peter Fenwick, Kevin Nelson, Mary Neal, Sam Parnia
Moderator: Steve Paulson
What happens when we die? Recent medical advances have led to increased reports of "out of body" or "near death" experiences. Can these experiences be explained, and what can we learn from the transformative accounts of those who have nearly died?
Tuesday, January 28, 2014 | 8:30 AM - 4:30 PM
Speakers: Ho Sung Cho (Ambrx), Nahor Haddish-Berhane (Pfizer), Sara Hurvitz (UCLA Medical Center), Omar Kabbarah (Genentech Inc.), Peter D. Senter (Seattle Genetics, Inc.), Dhaval K. Shah (The State University of New York at Buffalo), and Puja Sapra (Pfizer)
Antibody-drug conjugates (ADCs) promise safer, more effective therapies than standard anti-cancer drugs. This symposium highlights linker-payload and coupling chemistries, ADC development, biomarker and patient selection, and regulatory perspectives.
Wednesday, February 5, 2014 | 7:00 PM - 8:30 PM
Featuring: Allan Kellehear, Jeffrey J. Kripal, and Lani Leary
Moderator: Steve Paulson
How do we cope with the inevitability of our mortality? Experts in psychology, philosophy and sociology come together to share a multicultural perspective on death, dying, and what lies beyond.
Tuesday, February 18, 2014 | 8:30 AM - 4:30 PM
Speakers: John DiPersio (Washington University School of Medicine), William R. Drobyski (Medical College of Wisconsin), James Ferrara (University of Michigan), David L. Porter, MD, University of Pennsylvania Medical Center, Robert J. Soiffer (Dana-Farber Cancer Institute), Megan Sykes (Columbia University), Marcel RM van den Brink (Memorial Sloan Kettering Cancer Center)
Mechanisms that cause graft-versus-host disease (GvHD), a major cause of mortality after stem cell transplants, must be inhibited while preserving the graft-versus-tumor (GvT) response. Explore recent advances in separating GvHD from GvT effects.
Thursday, November 21, 2013 | 8:00 AM - 5:00 PM
Keynote Speaker: Sally Tinkle (IDA/Science and Technology Policy Institute)
Featured Speakers: Yechezkel (Chezy) Barenholz (Hebrew University-Hadassah Medical School), Raj Bawa (Bawa Biotech LLC and Rensselaer Polytechnic Institute), Gerrit Borchard (University of Geneva, University of Lausanne), Ricardo Carvajal (Hyman, Phelps & McNamara, P.C.), Neil Desai (Abraxis Bioscience, A wholly owned subsidiary of Celgene Corporation), Rogério Gaspar (University of Lisbon), Patrick Hunziker (University Hospital Basel), Laurent Levy (Nanobiotix), Scott E. McNeil (Nanotechnology Characterization Laboratory – Frederick National Laboratory for Cancer Research), Stefan Mühlebach (Vifor Pharma Ltd. and University of Basel), Ritu Nalubola (US Food and Drug Administration), Lawrence Tamarkin (Cytimmune)
Explore regulatory challenges in the nascent field of nanomedicines including the relevance and adequacy of existing frameworks, availability and expertise of regulators, and safety concerns.
Thursday, November 14, 2013 | 12:00 PM - 4:00 PM
Keynote Speaker: Nancy J. Cox (Centers for Disease Control and Prevention)
Speakers: Kathy Coelingh (MedImmune), Manon M. J. Cox (Protein Sciences), Ruben Donis (Centers for Disease Control and Prevention), Philip R. Dormitzer (Novartis Vaccines and Diagnostics), David P. Greenberg (Sanofi Pasteur US)
Evolution of the influenza virus and emergence of new viruses from animals pose a continuing challenge. H7N9, H1N1pdm and H5N1 are all sources of ongoing concern. Explore quadrivalent vaccines, efforts to boost efficacy, and recent FDA approvals.
Tuesday, November 12, 2013 | 7:00 PM - 8:30 PM
Featuring: Christopher Comfort, Barbara Coombs Lee, Sam Shemie, and Mildred Z. Solomon
Moderator: Steve Paulson
As lifesaving technologies continue to advance, how should medical and financial resources be used to prolong the lives of patients suspended between life and death? Panelists weigh the legal, ethical, and social implications of such decisions.
November 6 - 7, 2013
Organizers: Alan Cross (AstraZeneca), Sonya Dougal (formerly at The New York Academy of Sciences), Howard Feldman (University of British Columbia), Surya Kolluri (Bank of America), Ian Kremer (Leaders Engaged on Alzheimer's Disease), Tetsuyuki Maruyama (Takeda), Richard C. Mohs (Eli Lilly and Company), Jeffrey S. Nye (Janssen R&D), Ronald C. Petersen (Mayo Clinic), Gregory A. Petsko (Weill Cornell Medical College), Andrea Pfeifer (AC Immune), Thomas Rooney (Sanofi), Darryle D. Schoepp (Merck and Company, Inc.), Diane Stephenson (Critical Path Institute), Rudolph E. Tanzi (Harvard Medical School), John Q. Trojanowski (University of Pennsylvania), Diana L. van de Hoef (The New York Academy of Sciences), George Vradenburg (The Global CEO Initiative on Alzheimer's Disease), Michael Weiner (University of California, San Francisco), Michael Krams (Janssen R&D)
NIA Technical Advisor: Neil Buckholtz (National Institute on Aging/NIH)
This conference will convene leading industry, academic, and government stakeholders to discuss how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer our current drug development and evaluation systems, and identify innovative technologies and financing models. The outcome of this meeting will comprise a research agenda that will delineate the pathways needed to effectively treat and prevent Alzheimer's disease by 2025.
Edited by John T. Walkup
and Francis S. Lee
(Weill Cornell Medical College, New York, New York)
This Annals volume presents research on the unique developmental determinants of highly prevalent conditions in children and adolescents, including anxiety disorders, autism spectrum disorders, and pediatric neurological conditions.
Keynote Speakers: Alfred W. Sandrock Jr. (Biogen Idec) and Declan R. Walsh (Deferno Trust)
This eBriefing reviews new basic science and clinical findings on the pathogenesis, mitigation, cure, and risk stratification of PML.
Edited by Jaime Uribarri
(Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York)
This Annals volume explores the health implications of high dietary phosphorus intake for the general population and the current evidence associating excess phosphorus intake with potential risk for disease.
Free online access provided by the Sackler Institute for Nutrition Science
Edited by Robert Giuli
(Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar
(National Cancer Institute, Rockville, Maryland)
This Annals volume presents a compilation of expert views on topics related to esophagus physiology and disease presented at the World Organization for Specialized Studies on Diseases of the Esophagus 11th World Conference.
Foods high in antioxidants are believed to fight oxidative stress. But what is oxidative stress? Two scientists from a recent NYAS conference break it down and discuss whether antioxidants have superpowers.
Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.
Neuropsychologist Jeffrey Halperin is using behavioral therapy on preschoolers with attention deficit hyperactivity disorder (ADHD). He hopes to train their brains to develop in new ways and if effective, his therapies could offer permanent, drug-free treatment for the disorder.
Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.